CoChat

A review of serious adverse events linked with GLP-1 agonists in type 2 diabetes mellitus and obesity treatment

Tobaiqy, Mansour · 2024 · Pharmacological Reports

The DOI matches its Crossref record; 56 of the 58 references it cites were found in a registry or an index.

Abstract

Review of serious adverse events linked with GLP-1 agonists in T2D and obesity treatment. Evidence remains mixed on risks of pancreatitis, thyroid cancer, and other serious AEs.

Overview

Integrity signals

Registry

Crossref · 10.1007/s43440-024-00629-x

Cites

56 of 56 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 56 references

Cited by

See all 25

Metadata

Authors
Tobaiqy, M.
Affiliations
University of Jeddah (SA)
Corresponding author
Tobaiqy, Mansour
Venue
Pharmacological Reports
Published
2024-08-02
Volume
76
Issue
5
Pages
981-990
ISSN
  • 1734-1140 (ISSN-L)
  • 2299-5684
OpenAlex
W4401252114
Cited by
25
References
58
Citations by year
2026: 6 · 2025: 18 · 2024: 1
FWCI
1.46
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Pharmacological Reports (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
Keywords
GLP-1 receptor agonists, serious adverse events, drug safety, type 2 diabetes, obesity treatment, anaphylaxis, cardiovascular adverse events, gastrointestinal adverse effects, psychiatric adverse events
MeSH terms
Glucagon-Like Peptide-1 Receptor Agonists, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Obesity

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A review of serious adverse events linked with GLP-1 agonists in type 2 diabetes mellitus and obesity treatment. https://app.cochat.ai/papers/10.1007/s43440-024-00629-x
The paper
Tobaiqy, M. (2024). A review of serious adverse events linked with GLP-1 agonists in type 2 diabetes mellitus and obesity treatment. Pharmacological Reports. https://doi.org/10.1007/s43440-024-00629-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.